What are the most common bacterial organisms causing community-acquired pneumonia (CAP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Most Common Bacterial Organisms Causing Community-Acquired Pneumonia

Streptococcus pneumoniae is the predominant bacterial pathogen causing community-acquired pneumonia, accounting for 9-60% of cases depending on the population studied and diagnostic methods used. 1, 2

Primary Bacterial Pathogens

Streptococcus pneumoniae (Pneumococcus)

  • Remains the single most frequently isolated bacterial pathogen across all severity levels and care settings 1, 3
  • Accounts for 9-20% of outpatient CAP cases when identified by sputum culture 1
  • Represents 20-60% of hospitalized CAP cases 1
  • Increases to 16-37% when serological testing is included 1
  • Blood or pleural fluid cultures are positive in only 5-10% of cases despite being the most common pathogen 1, 2

Haemophilus influenzae

  • Second most common bacterial pathogen in most studies 1, 2
  • Accounts for 3-14% of CAP cases 1
  • Particularly common in patients with underlying chronic bronchopulmonary disease 1, 3
  • Most frequently isolated organism (38%) from patients with community-acquired pneumonia in office-based practices 4

Atypical Pathogens

  • Mycoplasma pneumoniae: 4-39% of cases, most common when serologic testing is performed (13-37% of outpatient episodes) 1, 2, 3
  • Chlamydophila pneumoniae: 0-20% of cases, up to 17% in outpatients 1, 2
  • Legionella species: 0.7-13% of cases, more common in severe pneumonia requiring ICU admission 1

Less Common Bacterial Pathogens

  • Moraxella catarrhalis: 0.5-3% of cases, primarily in patients with chronic lung disease 1
  • Staphylococcus aureus: Up to 10% of cases, especially during influenza outbreaks 1, 2
  • Gram-negative enteric bacilli: 0-3% in community settings, higher in patients with specific risk factors 1

Severity-Based Pathogen Distribution

Outpatient/Mild CAP

  • S. pneumoniae: 9-20% 1
  • M. pneumoniae: 13-37% 1, 3
  • C. pneumoniae: up to 17% 1
  • H. influenzae: 3-10% 1

Hospitalized Non-ICU Patients

  • S. pneumoniae: 20-60% 1
  • H. influenzae: 3-10% 1
  • Atypical pathogens (M. pneumoniae, C. pneumoniae): 40-60% combined 1
  • Legionella: variable, lower than ICU patients 1

ICU/Severe CAP

  • S. pneumoniae: remains most common (29% in ICU patients) 5
  • Legionella pneumophila: 26.3% in ICU patients 5
  • S. aureus: more frequent in severe disease 1
  • Gram-negative bacilli: increased frequency 1

Critical Diagnostic Limitations

No pathogen is identified in 20-70% of CAP cases despite comprehensive diagnostic testing. 1, 2, 3 This reflects:

  • Prior antibiotic treatment 1
  • Limitations of current diagnostic methods 1
  • Presence of viral infections (detected in up to 36% of cases) 1, 3
  • Mixed infections occurring in 8-40% of cases 1, 2

Geographic and Resistance Considerations

  • Macrolide-resistant S. pneumoniae varies by region (32-35% resistance in some U.S. areas) 4
  • High-level penicillin resistance in S. pneumoniae reaches 16% overall, highest in South Atlantic and East South Central U.S. regions 4
  • Beta-lactamase-producing H. influenzae ranges from 15-32% depending on geographic region 4
  • Community-acquired MRSA is an emerging pathogen associated with severe necrotizing pneumonia 1, 6

Clinical Implications for Empiric Therapy

The empiric antibiotic selection must cover S. pneumoniae as the primary target, with consideration for atypical pathogens based on clinical presentation and severity 1. The high frequency of unidentified pathogens (20-70%) and mixed infections (8-40%) supports broad-spectrum empiric coverage rather than narrow targeting 1, 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Bacterial Pneumonia Causes and Pathogens

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Community-Acquired Pneumonia Etiology

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Prospective study of community-acquired pneumonia of bacterial etiology in adults.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1999

Research

Changing needs of community-acquired pneumonia.

The Journal of antimicrobial chemotherapy, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.